COVID-19 Support
Precision Tools for your COVID-19 Workflow
To support labs pivoting to COVID-19 research, Gemini Bio is prioritizing products and services to assist its customers in four key areas: (1) cell culture, (2) viral harvesting and transport, (3) research tools, and (4) analytical instruments.
| Cell Culture | Viral Harvesting/Transport | Research Tools | Analytical Instruments |
|---|---|---|---|
| Human Serum | Viral Transport Media (Bulk or Custom Fill Sizes) | Cryostorage Medium | Moxi GO II Cell Analyzer |
| Gamma-Irradiated Fetal Bovine Serum | Saline and PBS | Growth Factors | Moxi V Cell Analyzer |
| Custom Media | Amphotericin B and Gentamicin | Cytokines | Moxi Z Cell Counter |
| Enzymatic Dissociation | Hanks’ Balanced Salt Solution (Bulk or Custom Fill Sizes) | Albumins | |
| Bioreactor Solutions | Sterile Conical Tubes & Pipettors |
Gemini Bio Wins Federal Contract to Support COVID-19 Testing
* Will be increasing domestic production of reagents from its California facility, as well as its manufacturing footprint
WEST SACRAMENTO, CA, June 11, 2020 – Gemini Bioproducts, LLC (“Gemini Bio”), a leading supplier of cell culture solutions and a portfolio company of BelHealth Investment Partners, LLC (“BelHealth”), today announced the receipt of a federal government contract award to supply critical products in support of the high demand for COVID-19 testing.
Gemini Bio Announces Its Dedicated Effort to Help Support COVID-19 Research
* Gemini Bio’s Key Products are Supporting the Fight against COVID-19
WEST SACRAMENTO, CA, April 29, 2020 – Gemini Bioproducts, LLC (“Gemini” or “Gemini Bio”), a leading supplier of cell culture solutions and a portfolio company of BelHealth Investment Partners, LLC (“BelHealth”), a New York-based healthcare private equity firm, today announced its effort to help support COVID-19 research.
According to the WHO, there are over 200 countries with 2.9 million confirmed cases and over 202,000 confirmed deaths, as of the time of this release.